Author/Authors :
Wojciech and Giermasz، نويسنده , , Adam and Nowis، نويسنده , , Dominika and Jalili، نويسنده , , Ahmad and Basak، نويسنده , , Grzegorz and Marczak، نويسنده , , Maria and Makowski، نويسنده , , Marcin and Czajka، نويسنده , , Anna and M?ynarczuk، نويسنده , , Izabela and Hoser، نويسنده , , Gra?yna and Stok osa، نويسنده , , Tomasz and Lewandowski، نويسنده , , Sebastian and Jak?bisiak، نويسنده , , Marek، نويسنده ,
Abstract :
Butyric acid has been known to inhibit growth and to induce differentiation of a variety of tumor cells. Butyrate-treated tumor cells have also been observed to undergo apoptosis. Although butyrate compounds have demonstrated antitumor activity in murine tumor models and have already been admitted to clinical trials in tumor patients, the exact mechanism of their antitumor effects has not been elucidated. The results of our study showed antitumor activity of tributyrin, a butyric acid prodrug, in murine melanoma model and are strongly suggestive that antiangiogenic effects could participate in antitumor effects of butyrate compounds in vivo.
Keywords :
Tributyrin , butyrate , Tumor therapy , melanoma , mouse
